Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07539454 · ClinicalTrials.gov registry record · Phase 2
Nirogacestat in Patients With Kaposi Sarcoma
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Not yet
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT07539454 is a Phase 2 study that has not yet begun recruiting, run by AIDS Malignancy Consortium. The registered enrollment target is 28 participants.
The verdict
NCT07539454, a Phase 2 study, has not yet begun recruiting, sponsored by AIDS Malignancy Consortium.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Chest Radiography
- PROCEDURE Skin Biopsy
- DRUG Nirogacestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-09-17 |
| Est. Completion | 2030-02-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07539454
The ClinicalTrials.gov registry entry for NCT07539454 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07539454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07539454 about?
NCT07539454 is a clinical study titled "Nirogacestat in Patients With Kaposi Sarcoma". This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other protei...
What is the current status of trial NCT07539454?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2026-09-17. Estimated completion is 2030-02-17.
What interventions are being tested in trial NCT07539454?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Chest Radiography (PROCEDURE), Skin Biopsy (PROCEDURE), Nirogacestat (DRUG).
Who is sponsoring clinical trial NCT07539454?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.